Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06568042 · ClinicalTrials.gov registry record · Phase 2
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
A Phase 2 study of Neuropathic Pain and Distal Sensory Polyneuropathy, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT06568042 is a Phase 2 study of Neuropathic Pain and Distal Sensory Polyneuropathy that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 450 participants, above the 88-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (411% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06568042, a Phase 2 study of Neuropathic Pain and Distal Sensory Polyneuropathy, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3848575
Study Locations (20)
Florida
- Accel Research Sites - St. Pete-Largo Clinical Research Unit - Largo
- Design Neuroscience Center - Miami Lakes
- Conquest Research - Orlando - Orlando
- Charter Research - Lady Lake - The Villages
- Encore Medical Research - Weston - Weston
- Conquest Research - Winter Park
Arizona
- MD First Research - Chandler - Chandler
- HOPE Research Institute - Phoenix
New York
- Mid Hudson Medical Research - New Windsor
- University of Rochester Medical Center - Rochester
North Carolina
- Asheville Neurology Specialists, PA - Asheville
- Center for Clinical Research - Winston-Salem
California
- Neuro-Pain Medical Center - Fresno
Colorado
- Alpine Clinical Research Center - Boulder
Iowa
- Integrated Clinical Trial Services, Inc. - West Des Moines
Massachusetts
- Lucida Clinical Trials - New Bedford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06568042
The ClinicalTrials.gov registry entry for NCT06568042 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (411% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06568042 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT06568042 about?
NCT06568042 is a clinical study titled "Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy". The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
What is the current status of trial NCT06568042?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 450 participants. The study started on 2024-08-22. Estimated completion is 2026-09.
What conditions does trial NCT06568042 study?
This clinical trial studies the following conditions: Neuropathic Pain, Distal Sensory Polyneuropathy.
What interventions are being tested in trial NCT06568042?
The interventions under investigation include: Placebo (DRUG), LY3848575 (DRUG).
Who is sponsoring clinical trial NCT06568042?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06568042 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy
RECRUITING · Phase 2
-
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
RECRUITING · Phase 2
-
Ginger Root Extract for Sciatic Pain Individuals
RECRUITING · Phase 2
-
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
COMPLETED · Phase 2
-
The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
COMPLETED · Phase 2
-
BMS-741672 for Diabetic Neuropathic Pain
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.